Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug;32(8):5477-5488.
doi: 10.1245/s10434-025-17366-x. Epub 2025 May 2.

Characterization of the Germline Pathogenic Mutational Landscape and Oncologic Outcomes Among 877 Patients with Invasive Lobular Carcinoma

Affiliations

Characterization of the Germline Pathogenic Mutational Landscape and Oncologic Outcomes Among 877 Patients with Invasive Lobular Carcinoma

Victoria D Huynh et al. Ann Surg Oncol. 2025 Aug.

Abstract

Purpose: There is a paucity of literature on germline pathogenic variants (gPVs) in patients with invasive lobular carcinoma (ILC). This study characterizes the landscape and compares clinicopathologic variables and treatment outcomes between those with and without gPVs.

Methods: A prospectively maintained institutional database was used to identify all patients diagnosed with nonmetastatic ILC who had germline genetic testing. Clinicopathologic characteristics and time to recurrence, contralateral cancer, and death were compared for patients with and without gPVs. Conditional hazard ratios, computed by Cox proportional hazards models, described associations between clinicopathologic factors, including gPV status, and cancer events.

Results: Of 4398 patients with nonmetastatic ILC seen between 1989 and 2024, 1170 patients were evaluated by genetic counselors; 877 underwent genetic testing. 10% (83/877) had gPVs, of whom 87% (72/83) had gPVs in known breast cancer predisposition genes; 13% had gPVs in preliminary evidence genes or genes not previously known to be breast cancer associated. Patients with gPVs were more likely to be younger than 40 years, be premenopausal, have high grade and triple-negative receptor status, and undergo mastectomy compared with those without gPV (p < 0.01). At median follow-up of 80 months (interquartile range, IQR 38-135 years), there was no significant difference in the time to contralateral breast cancer, distant or local-regional recurrence, and survival among patients with and without gPVs.

Conclusion: In this large single-institutional analysis, patients with ILC had a distinct landscape of gPVs in breast cancer and non-breast cancer predisposition genes. A significant proportion of patients with ILC have gPVs, and these findings have potentially actionable implications.

Keywords: Breast cancer; Genetic mutations; Germline pathogenic variants; Hereditary lobular breast cancer; Invasive lobular carcinoma; Outcomes; Survival.

PubMed Disclaimer

Conflict of interest statement

Disclosures: Dr. Kuerer reports receiving personal fees from NEJM Group Inc, UpToDate Inc, and McGraw-Hill Professional Inc outside the submitted work. Dr. Hunt reports personal fees from ArmadaHealth and AstraZeneca (medical advisory board) and Springer Nature (editor-in-chief of Current Breast Cancer Reports) and research funding to MD Anderson Cancer Center from Cairn Surgical, Eli Lilly & Co., and Lumicell. Dr. Mouabbi reports receiving personal fees from BostonGene, GE HealthCare, AstraZeneca, Aptitude Health, PreludeDX, and Community Health Media; grant support from Bristol Myers Squibb; and honoraria from Novartis, Gilead, Cardinal Health, Fresenius Kabi, Genentech, and OMNI Health. Dr. Mouabbi participates in the steering committee of AstraZeneca and Novartis and is the Scientific Advisory Board Chair of the Lobular Breast Cancer Alliance.

Similar articles

References

    1. Li CI, Anderson BO, Daling JR, Moe RE. Trends in incidence rates of invasive lobular and ductal breast carcinoma. JAMA. 2003;289(11):1421–4. - PubMed - DOI
    1. Foote FW Jr, Stewart FW. A histologic classification of carcinoma of the breast. Surgery. 1946;19:74–99. - PubMed
    1. Mendonsa AM, Na TY, Gumbiner BM. E-cadherin in contact inhibition and cancer. Oncogene. 2018;37(35):4769–80. - PubMed - PMC - DOI
    1. Molland JG, Donnellan M, Janu NC, Carmalt HL, Kennedy CW, Gillett DJ. Infiltrating lobular carcinoma–a comparison of diagnosis, management and outcome with infiltrating duct carcinoma. Breast. 2004;13(5):389–96. - PubMed - DOI
    1. Pestalozzi BC, Zahrieh D, Mallon E, et al. Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 international breast cancer study group clinical trials. J Clin Oncol. 2008;26(18):3006–14. - PubMed - DOI

MeSH terms

Substances

LinkOut - more resources